Bipolar Disorder or Schizophrenia |
3.12 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
FES SMG6 |
Intelligence (Savage-Jansen 2018) |
0.76 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
NUDCD3 |
Neuroticism (Nagel 2018) |
1.69 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
SLC22A1 |
Schizophrenia (2018) |
3.18 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
FES SMG6 |
Worry (Nagel 2018) |
1.14 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
SLC22A1 |
Breast Cancer |
2.23 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
CDKN2B CDKN2B-AS1 FES |
Coronary Artery Disease (CAD) |
25.60 |
9 |
6 |
13.3 |
0.98 |
2.1e-06 |
ADAMTS7 CDKN2B CDKN2B-AS1 MORF4L1 PSRC1 RP1-257A7.5 SLC22A3 SMG6 ST3GAL4 |
HDL Cholesterol |
2.20 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
PSRC1 ST3GAL4 |
LDL Cholesterol |
41.14 |
3 |
2 |
4.4 |
0.00 |
1.0e+00 |
NUDCD3 PSRC1 ST3GAL4 |
Schizophrenia (2014) |
3.46 |
2 |
2 |
4.4 |
0.00 |
1.0e+00 |
FES SMG6 |
Type 2 Diabetes (T2D) (2012) |
2.59 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
CDKN2B |
Blood Eosinophil Count |
0.48 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ST3GAL4 |
Blood Platelet Count |
2.72 |
5 |
2 |
4.4 |
0.53 |
3.6e-01 |
ADAMTS7 CDKN2B NUDCD3 SLC22A3 SMG6 |
Blood Red Count |
0.61 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
FES RP1-257A7.5 SMG6 |
Blood White Count |
2.03 |
3 |
2 |
4.4 |
0.00 |
1.0e+00 |
CDKN2B FES SMG6 |
Heel T-Score |
3.74 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
PSRC1 SMG6 |
BMI |
1.12 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
SLC22A3 SMG6 |
Height |
0.63 |
4 |
3 |
6.7 |
-0.75 |
2.5e-01 |
FES NUDCD3 PSRC1 SLC22A3 |
Waist Hip Ratio (WHR) |
2.01 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
ADAMTS7 SLC22A3 SMG6 |
Systolic Blood Pressure |
6.31 |
6 |
3 |
6.7 |
0.65 |
1.6e-01 |
CDH13 FES MORF4L1 RP1-257A7.5 SLC22A3 ST3GAL4 |
Smoking Status |
1.89 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FES |
Allergy or Eczema |
1.56 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
FES SMG6 |
Cardiovascular Disease |
7.34 |
5 |
3 |
6.7 |
0.98 |
4.6e-03 |
FES PSRC1 SLC22A1 SLC22A3 ST3GAL4 |
Respiratory disease |
1.66 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FES |
Lung FEV1/FVC ratio |
2.30 |
3 |
2 |
4.4 |
0.00 |
1.0e+00 |
AIDA PSRC1 SMG6 |
Lung FVC |
0.70 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
AIDA NUDCD3 |
Neuroticism |
1.56 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
NUDCD3 SLC22A1 |
Hair Pigment |
0.44 |
4 |
3 |
6.7 |
-0.83 |
1.7e-01 |
ADAMTS7 CDKN2B CDKN2B-AS1 FES |
Hand grip strength (left) |
1.62 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
FES RP1-257A7.5 |
Number of treatments/medications taken |
3.43 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
FES PSRC1 |
Sensitivity / hurt feelings |
1.59 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
FES |
Relative age of first facial hair |
1.27 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
SMG6 |
Systolic blood pressure, automated reading |
5.36 |
4 |
1 |
2.2 |
0.60 |
4.0e-01 |
CDH13 FES RP1-257A7.5 ST3GAL4 |
Angina |
24.74 |
9 |
9 |
20.0 |
0.99 |
8.5e-08 |
ADAMTS7 CDKN2B CDKN2B-AS1 FES MORF4L1 PSRC1 RP1-257A7.5 SLC22A1 SLC22A3 |
Medication: Metformin |
1.74 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
CDKN2B |
Pack years adult smoking proportion |
5.26 |
2 |
2 |
4.4 |
0.00 |
1.0e+00 |
ADAMTS7 MORF4L1 |
Impedance of leg (right) |
2.15 |
3 |
2 |
4.4 |
0.00 |
1.0e+00 |
AIDA FES SMG6 |
Leg fat-free mass (left) |
1.53 |
4 |
1 |
2.2 |
-0.40 |
6.0e-01 |
FES NUDCD3 SLC22A3 SMG6 |
Trunk fat percentage |
1.31 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
NUDCD3 SLC22A3 |
Hand grip strength (right) |
1.16 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RP1-257A7.5 |
Heel bone mineral density (BMD) T-score, automated (left) |
2.95 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
SMG6 |
High blood pressure |
5.74 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
FES SMG6 |
Hayfever, allergic rhinitis or eczema |
1.50 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FES |
Multivitamins +/- minerals |
2.60 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
MORF4L1 |
Medication: Atenolol |
7.10 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
FES PSRC1 |
Sitting height |
0.68 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
FES MORF4L1 SLC22A3 |
Chronic bronchitis/emphysema (father) |
3.31 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ADAMTS7 |
High blood pressure (mother) |
6.23 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
FES RP1-257A7.5 |
Body mass index (BMI) |
1.03 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
SMG6 |
Impedance of leg (left) |
2.10 |
3 |
2 |
4.4 |
0.00 |
1.0e+00 |
AIDA FES SMG6 |
Leg predicted mass (left) |
1.53 |
5 |
1 |
2.2 |
-0.40 |
5.1e-01 |
FES NUDCD3 PSRC1 SLC22A3 SMG6 |
Trunk fat mass |
1.41 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
NUDCD3 SLC22A3 |
Waist circumference |
1.15 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
SMG6 |
Number of incorrect matches in round |
1.36 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FES |
Past tobacco smoking |
2.07 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
CDKN2B-AS1 |
Alcohol usually taken with meals |
1.95 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FES |
Hair/balding pattern: Pattern 2 |
1.39 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
SMG6 |
Had other major operations |
1.98 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
NUDCD3 |
Heel bone mineral density (BMD) T-score, automated (right) |
2.53 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
SMG6 |
Heart attack |
21.39 |
8 |
8 |
17.8 |
0.99 |
2.5e-06 |
AIDA CDKN2B CDKN2B-AS1 FES PSRC1 RP1-257A7.5 SLC22A1 SLC22A3 |
Allergy |
1.28 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FES |
Medication: Ramipril |
4.07 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FES |
Medication: Simvastatin |
13.46 |
7 |
2 |
4.4 |
0.91 |
4.4e-03 |
CDKN2B CDKN2B-AS1 FES PSRC1 SLC22A1 SLC22A3 ST3GAL4 |
Illnesses of siblings |
4.03 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
FES SMG6 |
Weight |
1.42 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
NUDCD3 SLC22A3 SMG6 |
Impedance of arm (right) |
1.19 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
SMG6 |
Arm fat percentage (right) |
1.43 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
NUDCD3 |
Trunk fat-free mass |
1.39 |
3 |
2 |
4.4 |
0.00 |
1.0e+00 |
PSRC1 SLC22A3 SMG6 |
Hip circumference |
1.47 |
4 |
1 |
2.2 |
-0.62 |
3.8e-01 |
ADAMTS7 NUDCD3 SLC22A3 ST3GAL4 |
Father's age at death |
6.60 |
4 |
1 |
2.2 |
-1.00 |
1.1e-03 |
CDKN2B CDKN2B-AS1 FES PSRC1 |
Pulse rate |
1.48 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
SLC22A1 |
Medication: Ibuprofen (e.g. Nurofen) |
3.85 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
RP1-257A7.5 SLC22A3 |
Medication: Cholesterol lowering |
20.05 |
8 |
4 |
8.9 |
0.92 |
1.3e-03 |
AIDA CDKN2B CDKN2B-AS1 FES PSRC1 SLC22A1 SLC22A3 ST3GAL4 |
Lung cancer (father) |
4.84 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
ADAMTS7 MORF4L1 NUDCD3 |
Illnesses of mother |
4.40 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
CDKN2B FES |
Pulse wave Arterial Stiffness index |
3.63 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
FES RP1-257A7.5 |
Impedance of arm (left) |
1.16 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
SMG6 |
Arm fat mass (right) |
1.44 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
NUDCD3 SLC22A3 SMG6 |
Trunk predicted mass |
1.37 |
3 |
2 |
4.4 |
0.00 |
1.0e+00 |
PSRC1 SLC22A3 SMG6 |
Standing height |
0.61 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
NUDCD3 PSRC1 SLC22A3 |
Breastfed as a baby |
1.48 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FES |
Hair/balding pattern: Pattern 4 |
1.30 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FES |
Birth weight of first child |
3.34 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
FES |
Medication: Paracetamol |
2.03 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
RP1-257A7.5 |
Headache pain in last month |
4.28 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
FES RP1-257A7.5 |
Medication for cholesterol, blood pressure or diabetes |
9.67 |
3 |
2 |
4.4 |
0.00 |
1.0e+00 |
FES PSRC1 SLC22A1 |
Glaucoma (self-reported) |
5.60 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
CDKN2B CDKN2B-AS1 |
Medication: Amlodipine |
3.28 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
FES |
Birth weight |
1.92 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
FES |
Chronic bronchitis/emphysema (mother) |
1.90 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
MORF4L1 |
High blood pressure (siblings) |
3.77 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
FES SMG6 |
Body fat percentage |
1.29 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
NUDCD3 SLC22A3 |
Arm fat-free mass (right) |
1.23 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
PSRC1 SLC22A3 SMG6 |
Comparative body size at age 10 |
0.92 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
SMG6 |
Pulse wave peak to peak time |
3.57 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
FES RP1-257A7.5 |
Medication for pain relief, constipation, heartburn |
2.53 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RP1-257A7.5 |
Medication: Blood pressure |
5.33 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
FES SLC22A1 |
Angina (self-reported) |
25.66 |
9 |
9 |
20.0 |
0.99 |
5.1e-08 |
ADAMTS7 CDKN2B CDKN2B-AS1 FES MORF4L1 PSRC1 RP1-257A7.5 SLC22A1 SLC22A3 |
Migraine (self-reported) |
4.23 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
RP1-257A7.5 |
Medication: Ibuprofen |
3.93 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
RP1-257A7.5 SLC22A3 |
Mean time to correctly identify matches |
1.19 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FES |
Heart disease (mother) |
13.98 |
9 |
3 |
6.7 |
0.97 |
1.4e-05 |
ADAMTS7 CDKN2B CDKN2B-AS1 FES MORF4L1 RP1-257A7.5 SLC22A1 SLC22A3 ST3GAL4 |
Whole body fat mass |
1.46 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
NUDCD3 SLC22A3 |
Leg fat mass (right) |
1.18 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
NUDCD3 SLC22A3 |
Arm predicted mass (right) |
1.22 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
PSRC1 SLC22A3 SMG6 |
Pulse rate, automated reading |
1.49 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
AIDA RP1-257A7.5 |
Alcohol intake frequency. |
1.82 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RP1-257A7.5 |
Comparative height size at age 10 |
0.88 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
FES PSRC1 SLC22A3 |
Chest pain or discomfort |
2.79 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
CDKN2B |
Medication: Aspirin |
12.49 |
6 |
5 |
11.1 |
1.00 |
1.9e-05 |
CDKN2B CDKN2B-AS1 FES PSRC1 SLC22A1 SLC22A3 |
Hypertension (Self-reported) |
5.96 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
FES SMG6 |
Smoking status: Previous |
1.98 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
CDKN2B-AS1 |
Whole body fat-free mass |
1.44 |
4 |
1 |
2.2 |
-0.49 |
5.1e-01 |
FES PSRC1 SLC22A3 SMG6 |
Leg fat-free mass (right) |
1.56 |
5 |
1 |
2.2 |
-0.43 |
4.7e-01 |
FES NUDCD3 PSRC1 SLC22A3 SMG6 |
Arm fat percentage (left) |
1.36 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
NUDCD3 |
Handedness (chirality/laterality): Left-handed |
1.60 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FES |
Long-standing illness, disability or infirmity |
1.43 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
CDKN2B |
Medication for cholesterol |
6.13 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
FES PSRC1 SLC22A3 |
Mineral and other dietary supplements |
2.67 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FES |
Breast cancer (self-reported) |
2.49 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
CDKN2B |
Medication: Aspirin |
12.75 |
6 |
5 |
11.1 |
1.00 |
1.1e-05 |
CDKN2B CDKN2B-AS1 FES PSRC1 SLC22A1 SLC22A3 |
Illnesses of father: None of the above (group 1) |
10.51 |
5 |
2 |
4.4 |
-0.99 |
5.1e-04 |
CDKN2B CDKN2B-AS1 FES SLC22A3 ST3GAL4 |
Forced expiratory volume in 1-second (FEV1), predicted percentage |
2.22 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
ADAMTS7 MORF4L1 NUDCD3 |
Whole body water mass |
1.41 |
4 |
1 |
2.2 |
-0.50 |
5.0e-01 |
FES PSRC1 SLC22A3 SMG6 |
Leg predicted mass (right) |
1.57 |
5 |
1 |
2.2 |
-0.43 |
4.7e-01 |
FES NUDCD3 PSRC1 SLC22A3 SMG6 |
Arm fat mass (left) |
1.46 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
NUDCD3 SLC22A3 SMG6 |
Number of self-reported non-cancer illnesses |
3.11 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
NUDCD3 |
Mother's age at death |
2.02 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
SLC22A1 |
Eye problems/disorders: Glaucoma |
6.68 |
2 |
2 |
4.4 |
0.00 |
1.0e+00 |
CDKN2B CDKN2B-AS1 |
Medication: Blood pressure |
5.60 |
4 |
1 |
2.2 |
0.86 |
1.4e-01 |
ADAMTS7 FES SLC22A3 SMG6 |
Supplements: Fish oil (including cod liver oil) |
2.59 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
NUDCD3 SLC22A3 |
High cholesterol (Self-reported) |
21.46 |
6 |
4 |
8.9 |
0.86 |
2.9e-02 |
FES NUDCD3 PSRC1 SLC22A1 SLC22A3 ST3GAL4 |
Medication: Bendroflumethiazide |
3.76 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
ADAMTS7 FES |
Medication: Paracetamol |
1.75 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RP1-257A7.5 |
Medication: Lisinopril |
1.83 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FES |
Medication: Atorvastatin |
14.26 |
5 |
3 |
6.7 |
0.97 |
6.1e-03 |
CDKN2B CDKN2B-AS1 PSRC1 SLC22A1 SLC22A3 |
Illnesses of father: High blood pressure |
4.27 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
FES |
Ever smoked |
1.64 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FES |
Basal metabolic rate |
1.40 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
PSRC1 SLC22A3 SMG6 |
Arm fat-free mass (left) |
1.21 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
PSRC1 SLC22A3 SMG6 |
Number of operations (self-reported) |
2.02 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
NUDCD3 |
Risk taking |
2.17 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FES |
Diastolic blood pressure, automated reading |
6.99 |
6 |
3 |
6.7 |
-0.07 |
9.0e-01 |
ADAMTS7 CDH13 CDKN2B CDKN2B-AS1 FES MORF4L1 |
Vascular/heart problems diagnosed by doctor |
7.11 |
4 |
1 |
2.2 |
-0.99 |
1.2e-02 |
FES SLC22A3 SMG6 ST3GAL4 |
Cholesterol lowering medication |
11.17 |
4 |
2 |
4.4 |
0.90 |
9.6e-02 |
CDKN2B PSRC1 SLC22A1 SLC22A3 |
Pain experienced in last month |
1.37 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RP1-257A7.5 |
Basal cell carcinoma (self-reported) |
2.69 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
CDKN2B |
Heart attack/myocardial infarction (self-reported) |
21.48 |
8 |
8 |
17.8 |
0.99 |
3.7e-06 |
AIDA CDKN2B CDKN2B-AS1 FES PSRC1 RP1-257A7.5 SLC22A1 SLC22A3 |
Heart disease (siblings) |
11.45 |
8 |
1 |
2.2 |
0.98 |
1.3e-05 |
ADAMTS7 AIDA CDKN2B-AS1 FES PSRC1 RP1-257A7.5 SLC22A1 SLC22A3 |
Pack years of smoking |
4.86 |
2 |
2 |
4.4 |
0.00 |
1.0e+00 |
ADAMTS7 MORF4L1 |
Impedance of whole body |
1.64 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
SMG6 |
Leg fat mass (left) |
1.13 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
NUDCD3 SLC22A3 |
Arm predicted mass (left) |
1.24 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
PSRC1 SLC22A3 SMG6 |